Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ashton

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2013
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the ratCarl-Christer Johansson, Peter Gennemark, Per Artursson, et al.
European Journal of Clinical Pharmacology|April 17, 2002
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxisMita M Thapar, Michael Ashton, Niklas Lindegårdh, et al.
Nano Letters|July 27, 2017
Two-Dimensional Intrinsic Half-Metals With Large Spin GapsMichael Ashton, Dorde Gluhovic, Susan B Sinnott, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 2, 2023
<i>N, N</i>-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an <i>in vitro</i> investigationEmma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström, et al.
British Journal of Clinical Pharmacology|January 29, 2005
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extractionToufigh Gordi, Rujia Xie, Nguyen V Huong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 20, 2008
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimensDoaa A Elsherbiny, Sara A Asimus, Mats O Karlsson, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9Ulrika S H Simonsson, Britt Jansson, Trinh Ngoc Hai, et al.
Sexually Transmitted Diseases|October 29, 2005
Knowledge about sexually transmitted diseases in women among primary care physiciansHarold C Wiesenfeld, Keisha Dennard-Hall, Robert L Cook, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 12, 2022
Development and application of a highly sensitive LC-MS/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasmaEmma Eckernäs, Adam Bendrioua, Chiara Cancellerini, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisininRita Piedade, Elke Schaeffeler, Stefan Winter, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2013
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the ratCarl-Christer Johansson, Peter Gennemark, Per Artursson, et al.
European Journal of Clinical Pharmacology|April 17, 2002
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxisMita M Thapar, Michael Ashton, Niklas Lindegårdh, et al.
Nano Letters|July 27, 2017
Two-Dimensional Intrinsic Half-Metals With Large Spin GapsMichael Ashton, Dorde Gluhovic, Susan B Sinnott, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 2, 2023
<i>N, N</i>-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an <i>in vitro</i> investigationEmma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström, et al.
British Journal of Clinical Pharmacology|January 29, 2005
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extractionToufigh Gordi, Rujia Xie, Nguyen V Huong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 20, 2008
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimensDoaa A Elsherbiny, Sara A Asimus, Mats O Karlsson, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9Ulrika S H Simonsson, Britt Jansson, Trinh Ngoc Hai, et al.
Sexually Transmitted Diseases|October 29, 2005
Knowledge about sexually transmitted diseases in women among primary care physiciansHarold C Wiesenfeld, Keisha Dennard-Hall, Robert L Cook, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 12, 2022
Development and application of a highly sensitive LC-MS/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasmaEmma Eckernäs, Adam Bendrioua, Chiara Cancellerini, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisininRita Piedade, Elke Schaeffeler, Stefan Winter, et al.
Pageof 7